Comparative Pharmacology
Head-to-head clinical analysis: APADAZ versus KADIAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APADAZ versus KADIAN.
APADAZ vs KADIAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APADAZ is a combination of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. Hydrocodone acts as a full mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen's mechanism involves inhibition of cyclooxygenase (COX) enzymes, particularly in the CNS, and modulation of serotonergic pathways, contributing to analgesia and antipyresis.
Mu-opioid receptor agonist; modulates pain perception and emotional response to pain.
Each tablet contains benzhydrocodone 4.08 mg (hydrocodone 3.33 mg) and acetaminophen 325 mg. One to 2 tablets every 4 to 6 hours as needed for pain; maximum 12 tablets per 24 hours.
20-100 mg orally every 12 hours; titration based on pain severity and prior opioid exposure.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours for benzhydrocodone; context: immediate-release, dosing every 4-6 hours.
Terminal elimination half-life of morphine: 2–4 hours; KADIAN extended-release formulation: effective half-life ~12 hours due to prolonged absorption, dosing q12h or q24h
Renal: ~90% as conjugates, ~10% unchanged; fecal: minimal; enterohepatic recirculation occurs.
Renal: primarily as morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G); ~90% of total elimination is renal, with 10% biliary/fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic